Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Mar;28(5):1713-23.
doi: 10.1128/MCB.01360-07. Epub 2007 Dec 26.

Beta-catenin expression results in p53-independent DNA damage and oncogene-induced senescence in prelymphomagenic thymocytes in vivo

Mai Xu  1 , Qing Yu, Ramesh Subrahmanyam, Michael J Difilippantonio, Thomas Ried, Jyoti Misra Sen
Affiliations

Beta-catenin expression results in p53-independent DNA damage and oncogene-induced senescence in prelymphomagenic thymocytes in vivo

Mai Xu et al. Mol Cell Biol. 2008 Mar.

Abstract

The expression of beta-catenin, a potent oncogene, is causally linked to tumorigenesis. Therefore, it was surprising that the transgenic expression of oncogenic beta-catenin in thymocytes resulted in thymic involution instead of lymphomagenesis. In this report, we demonstrate that this is because the expression of oncogenic beta-catenin induces DNA damage, growth arrest, oncogene-induced senescence (OIS), and apoptosis of immature thymocytes. In p53-deficient mice, the expression of oncogenic beta-catenin still results in DNA damage and OIS, but the thymocytes survive and eventually progress to thymic lymphoma. beta-Catenin-induced thymic lymphomas are distinct from lymphomas that arise in p53(-/-) mice. They are CD4(-) CD8(-), while p53-dependent lymphomas are largely CD4(+) CD8(+), and they develop at an earlier age and in the absence of c-Myc expression or Notch1 signaling. Thus, we report that oncogenic beta-catenin-induced, p53-independent growth arrest and OIS and p53-dependent apoptosis protect developing thymocytes from transformation by oncogenic beta-catenin.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Expression of stabilized β-catenin in thymocytes causes growth arrest and cellular senescence. (A) Abundance of human (transgenic) β-catenin mRNA relative to GAPDH in sorted CAT-Tg DN2, DN3, and DN4 cells analyzed by real-time PCR (n = 3). Shown is Western blot analysis of endogenous murine (upper bands) and transgenic human (lower bands) β-catenin protein (representative of data from five mice). (B) BrdU incorporation in electronically gated DN4 thymocytes from C57BL/6 and CAT-Tg mice. The graph shows average data from more than three mice for each genotype in one experiment and is representative of three experiments. (C) Real-time RT-PCR analysis of the expression of cell cycle regulators in sorted DN4 thymocytes from C57BL/6 (n = 3) and CAT-Tg (n = 3) mice. (D) Real-time PCR analysis of SA genes in sorted DN4 thymocytes from C57BL/6 and CAT-Tg mice (n = 3). (D) SA β-galactosidase activity in thymic cryosections from C57BL/6 and CAT-Tg mice (representative of n = 4).
FIG. 2.
FIG. 2.
Enhanced DNA damage and p53-dependent apoptosis in CAT-Tg mice. (A) Immunofluorescence staining of phosphorylated histone γH2AX in fixed DN (eight CAT-Tg and C57BL/6 mice) and DP (two CAT-Tg and two C57BL/6 mice) thymocytes. The bar graph shows the percentage of γH2AX-positive cells in C57BL/6 DN and CAT-Tg DN thymocytes (see Fig. S3 in the supplemental material). (B) Three examples of γH2AX foci in CAT-Tg DN thymocytes shown at a higher magnification. (C) Annexin V staining of DN4 thymocytes (electronically gated) from C57BL/6 and CAT-Tg mice. The numbers in the graph are an average of data from more than three mice for each genotype in one experiment that is representative of six experiments. (D) Real-time RT-PCR analysis of the expression of p53 pathway-associated genes in sorted DN4 thymocytes from CAT-Tg (n = 3) and C57BL/6 (n = 3) mice.
FIG. 3.
FIG. 3.
Expression of stabilized β-catenin induces p53-independent DNA damage and OIS and p53-dependent apoptosis in thymocytes. (A) Total number of thymocytes in p53−/− CAT-Tg mice at different ages. The first two bars (light blue) represent the initial decrease in thymic cellularity in young mice, and the right bar (dark blue) indicates regained thymic cellularity after 66 days of age. (B) Immunofluorescence staining of γH2AX in fixed DN cells from C57BL/6, p53−/−, and p53−/− CAT-Tg mice. (C) SA β-galactosidase expression in cryosections from a 50-day-old lymphoma-free p53−/− CAT-Tg mouse with a small thymus. (D) Annexin V staining of electronically gated DN4 thymocytes from C57BL/6, CAT-Tg, and lymphoma-free p53−/− CAT-Tg mice (≤65 days old). The data are averages of data from more than three mice for each genotype in one experiment, which is representative of four experiments. (E) BrdU incorporation in electronically gated DN thymocytes from young and lymphoma-free p53−/− CAT-Tg mice (growth arrested) and relatively old lymphoma-bearing p53−/− CAT-Tg mice (proliferating). The graph shows the average of data from more than two mice for each genotype in one experiment and is representative of two experiments. (F) RT-PCR analysis of the expression of cell cycle regulators in sorted DN thymocytes from young lymphoma-free p53−/− CAT-Tg mice (growth arrested) (n = 3) and old lymphoma-bearing p53−/− CAT-Tg mice (proliferating) (n = 3).
FIG. 4.
FIG. 4.
Stabilized β-catenin in a p53-deficient genetic background causes thymic lymphoma and death of the mice at an early age. (A) Kaplan-Meier plot showing time-to-death latencies in CAT-Tg (n = 10), p53−/− CAT-Tg (n = 14), and p53+/− CAT-Tg (n = 30) mice. Kaplan-Meier plots for p53−/− and p53+/− mice were reported previously (41). The insert indicates the median time to death of mice with various genotypes. (B) Numbers of mice with thymic hyperplasia in a cohort of p53−/− CAT-Tg, p53+/− CAT-Tg, and p53−/− mice. (C) Thymus, spleen, and lymph nodes from diseased p53−/− CAT-Tg mice (70 days old) (left) and C57BL/6 mice (56 days old) (right). (D) Immunohistochemical analysis of CD3ɛ expression (blue) in cryosections of livers from a diseased p53−/− CAT-Tg mouse (84 days old) and a CAT-Tg mouse (84 days old) at 20-fold magnification. (E to G) Thymocytes (E), splenocytes (F), and lymph node cells (G) from C57BL/6 mice (left) and two p53−/− CAT-Tg mice (p53−/− CAT-Tg-1 mice [79 days old] and p53−/− CAT-Tg-2 mice [84 days old] [two right panels]) were stained with antibodies to the TCRβ chain, CD4, and CD8 and analyzed by flow cytometry. Histogram of TCRβ chain expression and dot plots for CD4 and CD8 expression on gated TCRβint/hi splenocytes and lymph node cells are shown.
FIG. 5.
FIG. 5.
Lymphoma progression in p53−/− CAT-Tg mice and loss of p53 function are essential for the formation of β-catenin-triggered DN thymic lymphoma. (A to D) Representative fluorescence-activated cell sorter profiles showing forward scatter (FSC) and side scatter (SSC) (top) and cell surface staining of CD4 and CD8 (middle) and TCRβ (bottom) in electronically gated CD4− CD8− DN cells of total thymocytes from C57BL/6 mice (n > 10) (A), CAT-Tg mice (n > 10) (B), p53−/− CAT-Tg mice (n > 4) at different ages as indicated (C), and p53+/− CAT-Tg mice bearing thymic lymphoma (n > 5). (E) Allele-specific p53 genomic PCR detects normal wild-type and mutant p53 allele (tail) tissues but largely the mutant allele in the thymic lymphoma (representative of three independent thymic lymphomas).
FIG. 6.
FIG. 6.
p53−/− CAT-Tg DN lymphomas are immature pre-DP cells and are distinct from p53−/− DP/SP lymphomas. (A) Representative fluorescence-activated cell sorter profiles showing forward scatter (FSC) and side scatter (SSC) (top) and cell surface staining of CD4, CD8 (middle), and TCRβ (bottom) on electronically gated CD4− CD8− DN cells of total thymocytes from a thymic lymphoma-bearing 91-day-old p53−/− mouse. (B) Abundance of Deltex-1 and c-Myc mRNA relative to GAPDH in DN thymocytes from C56BL/6 and lymphoma-bearing p53−/− CAT-Tg mice analyzed by real-time PCR. (C) Total thymocytes from C57BL/6 and lymphoma-bearing p53−/−CAT-Tg mice were stained with a group of TCRα antibodies. (Top) Surface expression of TCRα on thymocytes electronically gated to exclude DP, SP, and NK cells. (Bottom) Surface expression of TCRα on electronically gated DP and SP thymocytes. (D) PCR analysis of rearranged TCRαV5H+F3+2C-J2T11 gene segments using the same amount of genomic DNA purified from thymocytes. (E) PCR analysis of rearranged TCRβD2-Jβ2 gene segments using same amount of genomic DNA purified from total thymocytes. (F) Chromosome structural aberrations in p53−/− CAT-Tg lymphomas. From left to right, a normal chromosome 6 (left), a deleted chromosome 6 (right), a chromatid break on chromosome 11, and chromosome translocations illustrated by T(10;17) (left) and T(4;6) (right) are shown; centromere fusions were sometimes simple, containing material from the same chromosome, as in Rb(3.3) on the left, and sometimes more complex, as in Rb[5.T(5;4)] on the right. Polycentric chromosomes resulted from the fusion of chromosomes in a tail-to-tail orientation, as in the dicentric chromosome on the left, or in a head-to-tail orientation, as occurred multiple times in the pentacentric chromosome on the right. (G) Spectral karyotype of p53−/− CAT-Tg lymphomas. The top metaphase is a pseudotetraploid cell (n = 80) with deletions of chromosome 5, a general loss of chromosome 13, and a gain of chromosome 17. Also illustrated at the bottom left side are two chromosome fragments containing centromeres (black arrows). The bottom cell is a pseudotriploid (n = 60) karyotype with a complex rearrangement between chromosomes 10 and 16 containing four centromeres (red arrows).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bartkova, J., N. Rezaei, M. Liontos, P. Karakaidos, D. Kletsas, N. Issaeva, L. V. Vassiliou, E. Kolettas, K. Niforou, V. C. Zoumpourlis, M. Takaoka, H. Nakagawa, F. Tort, K. Fugger, F. Johansson, M. Sehested, C. L. Andersen, L. Dyrskjot, T. Orntoft, J. Lukas, C. Kittas, T. Helleday, T. D. Halazonetis, J. Bartek, and V. G. Gorgoulis. 2006. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444633-637. - PubMed
    1. Braig, M., S. Lee, C. Loddenkemper, C. Rudolph, A. H. Peters, B. Schlegelberger, H. Stein, B. Dorken, T. Jenuwein, and C. A. Schmitt. 2005. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436660-665. - PubMed
    1. Campisi, J. 2001. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 11S27-S31. - PubMed
    1. Chen, H. T., A. Bhandoola, M. J. Difilippantonio, J. Zhu, M. J. Brown, X. Tai, E. P. Rogakou, T. M. Brotz, W. M. Bonner, T. Ried, and A. Nussenzweig. 2000. Response to RAG-mediated VDJ cleavage by NBS1 and gamma-H2AX. Science 2901962-1965. - PMC - PubMed
    1. Chen, Z., L. C. Trotman, D. Shaffer, H. K. Lin, Z. A. Dotan, M. Niki, J. A. Koutcher, H. I. Scher, T. Ludwig, W. Gerald, C. Cordon-Cardo, and P. P. Pandolfi. 2005. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436725-730. - PMC - PubMed

Publication types